CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial.
The Lancet. Haematology（2023）
摘要
Celyad Oncology.
更多查看译文
关键词
refractory acute myeloid leukaemia,myelodysplastic syndromes,multiple myeloma,d-based,t-cell
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要